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Introduction
Despite	 some	 progress,	 cancer	 remains	 a	
major	 research	 challenge.	 Nowadays,	 research	
for	new	anticancer	drugs	is	a	very	active	domain	
(Sevastre	 et al.,	 2017).	 Plants	 have	 played	 an	
important	role	as	a	source	of	effective	anticancer	
agents	 and	 it	 is	 significant	 that	 over	 60%	 of	
currently	 used	 anticancer	 agents	 are	 derived	
in	 one	 way	 or	 another	 from	 natural	 sources	









plant	 that	 is	 endemic	 to	 southern	 Europe	 and	
Asia	 and	 is	 widely	 used	 for	 both	 dietary	 and	
medicinal	composition.	Salvia	is	the	largest	genus	
of	the	Lamiaceae	family,	with	around	900	species	
described	 worldwide.	 It	 has	 different	 biological	
activities	 that	 are	 manifested	 by	 its	 different	
components,	and	this	“panacea”	reputation	is	often	
just	linked	to	its	essential	oils,	even	if	its	chemical	
composition	 is	 different	 due	 to	 genetic	 aspects	
and	environmental	factors	(Privietera	et al.,	2019).	
Previous	studies	have	demonstrated	that	the	active	
principles	 in	 Salvia officinalis	 are	 the	 phenolic	
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The	 current	 study	demonstrated	 the	 superior	 in vivo	 antitumor	activity	of	 the	 association	between	Salvia 
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compounds:	 caffeic	 acid,	 carnosic	 acid,	 carnosol,	
kaempferol,	 oleanolic	 acid,	 rosmarinic	 acid	 and	
ursolic	 acid	 and	 the	 essesntial	 oils:	 α-pinene,	
1,8-cineole,	 linalool,	 limonene,	borneol,	myrcene,	
β-caryophyllene,	 spathulenol,	 β-caryophyllene	











L.	 and	Doxorubicin	 increase	 the	antitumor	effect	
of	 Doxorubicin.	 The	 second	 objective	 was	 to	
follow	the	ability	of	Salvia officinalis	L.	to	achieve	
protection	 against	 the	 side	 effects	 caused	 by	
the	 tumor	 grouth	 and	 to	 demonstrate	 its	 lack	
of	 toxicity.	The	study	 is	a	 follow	up	of	an	 in vitro 
study	performed	also	on	Salvia officinalis	L.	when	
we	 demonstrated	 its	 antioxidant	 and	 antitumor	
properties	(Marian	et al.,	2018).
Materials and methods
Plant material and preparation of the 
extract
The leaves	 of Salvia officinalis L.	 (Salviae 





For	 the	 extraction	 of	 bioactive	 compounds	
from	 the	 plant	 product,	 a	 70%	 hydroalcoholic	
mixture	 (1:10	 g/v)	 was	 used	 as	 an	 extraction	
solvent.	The	extraction	mixture	was	subjected	to	a	
shaking	operation	using	a	magnetic	homogenizer	
for	 20	 minutes	 followed	 by	 sonication	 for	 5	
minutes	 (Romanian	Pharmacopoeia	10th	edition).	
At	 the	 end	 of	 the	 extraction,	 the	 hydroalcoholic	
extracts	were	subjected	to	centrifugation	and	the	
supernatants	 evaporated	 to	 dryness	 in	 a	 rotary	
evaporator.	 The	 dry	 extract	was	 dispersed	 in	 10	
mL	distilled	water	and	then	frozen	at	-25°C.	Finally,	
they	 were	 brought	 to	 the	 lyophilizer	 and	 the	
lyophilized	extracts	were	weighed	and	transferred	
to	a	dry	sealed	container.
Animal care and experimental procedures
The	experiments	on	animals	were	performed	
according	 to	 the	 Directive	 2010/63/EU	 and	
National	 low	 no.	 43/11.04.2014.	 The	 study	
was	 performed	 into	 the	 Establishment	 for	 the	
breeding	 and	 use	 for	 laboratory	 animals	 of	 the	
University	 of	 Medicine	 and	 Pharmacy	 “Iuliu-	
Hatieganu”	 Cluj-Napoca;	 the	 experiment	 was	
approved	by	The	Bioethical	Board	of	UMF	“Iuliu-
Hațieganu”	 Cluj-Napoca,	 and	 authorized	by	 state	
veterinary	 authority.	 The	 animals	were	 caged	 in	
polycarbonate	cages,	at	controlled	temperature	(of	
21-22°C),	 humidity	 (40-60%)	 and	 12/12h	 light/
dark	 cycle.	 Standard	 lab	 chow,	 provided	 by	 the	
National	 Institute	 for	Research	and	Development	








Group	 II	 –	 tumor	 control	 group	 (EAC).	 Mice	
implanted	with	Ehrlich	ascites	carcinoma	cells,	
106	 ascitic	 cells	 each,	 on	 day	 0,	 and	 placebo	
therapy	 intraperitoneally	 (0.5	 ml	 saline	
physiological	solution	/	mice,	i.p);
Group	 III	 –	 EAC	 and	doxorubicin	 administration.	
Accordingly	 to	 manufacturer	 specification,	
the	 LD
50
	 for	 doxorubicin	 chloride,	 in	 mice,	 in	
intraperitoneally	 administration,	 is	 21.9	 mg/
kg.	 The	 normal	 therapeutically	 dose	 being	
approximately	10	 times	 lower,	during	 the	pre-
sent	 experiment,	 mice	 received	 2.5	 mg	 doxo-
ru	bicin	 chloride/b.w.	 (Adriblastina	 10	 mg,	
Pfizer)	 dissolved	 in	 sterile	 saline	 solution,	 up	
to	 0.5	 ml	 per	 animal.	 The	 mentioned	 doses	
were	administered	in	the	1st	and	6th	day	of	the	
experiment.
Group	 IV	 –	 EAC	 and	 doxorubicin	 +	 Salvia offici-





has	 been	 established	 following	 preliminary	
toxicity	studies.
14	days	after	EAC	implantation,	blood	samples	
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induced	by	prolonged	narcosis.	Blood	hematology	
(complete	 blood	 count)	 was	 investigated	 with	
Abacus	 Junior	 Vet,	 Diatron,	 3	 Diff	 Messtechnik,	
Hungary.	 Blood	 chemistry	 (urea,	 creatinine	 and	
transaminase)	was	measured	 using	 screen	 point	
semiautomatic	 analyzer,	 STAT	 -	 FAX	 1904	 Plus,	
Global	Medical	Instrumentation,	Inc.	6511	Bunker	
Lake	Blvd.	Ramsey	Minesota,	55303	USA	by	using	




immediately	 after	 euthanasia,	 and	 transferred	
in	 phosphate	 buffer	 solution	 (pH	 7.4,	 at	 4°C).	
Then,	 the	 samples	 were	 subjected	 to	 repeated	
centrifugations	 (at	 4°C),	 first	 at	 4.500	 rpm	 for	
5	min,	 then	at	12.000	rpm	for	3	min,	 in	order	 to	
obtain	 a	 dense	 cell	 suspension,	 which	 was	 also	
stored	 at	 deep	 freezer	 until	 further	 use.	 The	
tumor	cell	concentration	was	counted	in	a	Burker	
chamber	(dilution	1:10)	and	the	cell	viability	was	
assessed	 by	 Tripan	 blue	 staining	 (0.4%	 in	 PBS).	
Body	 weight	 was	measured	 at	 the	 beginning,	 in	
the	days	3,	6,	9,	12	and	at	the	end	of	the	study.	At	




All	 data	 are	 reported	 as	 the	 mean	 ±	 SEM.	




comparisons	between	 the	volume	of	 ascitic	 fluid	
and	variation	of	viable	cells	 concentration,	while	




were	 obtained	 using	 GraphPad	 Prism	 version	
5.0	 for	Windows,	 GraphPad	 Software,	 San	 Diego	
California	USA.
Results and discussion
The	 first	 objective	 of	 this	 study	 was	 to	
demonstrate	the	in vivo	antitumor	effect	of	Salvia 
officinalis	L.	harvested	from	Romania	and	the	fact	
that	 the	 association	 between	 Salvia officinalis	 L.	
and	doxorubicin	 increase	 the	 antitumor	effect	 of	
doxorubicin.
The	 body	 weight,	 as	 a	 measure	 of	 Ehrlich	
ascites	 accumulation	 in	 the	 peritoneal	 cavity	




gain.	 The	 differences	 were	 visible	 starting	 from	
the	third	day	of	the	study.	Both	therapies	proved	




tionally	 with	 the	 body	 weight	 gain.	 It	 has	 been	
found	a	significant	decrease	in	the	ascitic	volume	
(Fig.2A)	 and	 in	 the	 tumor	 cell	 concentration	
(Fig.2B)	 for	 both	 EAC	 +	 doxorubicin	 and	 EAC	
+	 doxorubicin	 +	 Salvia officinalis	 L.	 groups	 as	
compared	with	 the	 tumor	control	group.	For	 the	
EAC	+	doxorubicin	+	Salvia officinalis	L.	group	the	





ru	bicin	 therapy	 in	 a	 significant	 manner.	 The	
association	 between	 doxorubicin	 and	 Salvia 
officinalis	 L.	 provide	 a	 better	 antiproliferative	
effect	 as	 compared	 to	 doxorubicin	 alone.	 In	 fact,	
all	the	values	that	reflect	the	tumor	development	
(difference	 in	 body	 weight,	 EAC	 volume	 and	
cellular	 concentration)	 were	 improved	 in	
significant	manner	(Figures	1,	2	A,	B).
The	 mechanism	 of	 action	 for	 doxorubicin	




Antitumor	 activity	 of	 Salvia officinalis L.	 is	
due	 to	 its	 anti-angiogenic,	 anti-migratory	 and	
anti-proliferative	effects	 (Keshavarz	et al.,	2011).	
Most	 primary	 solid	 tumors	 are	 dependent	 on	
angiogenesis	 for	 survival,	 growth,	 invasion	 and	
metastasis.	Therefore,	 targeting	 the	angiogenesis	
process	 has	 become	 one	 of	 the	 important	
strategies	 in	 the	 treatment	 and	 prevention	 of	
cancer	 progression	 (Pandya	 et al.,	 2006).	 In	 the	
angiogenesis	 process,	 vascular	 endothelial	 cells	
migrate	 out	 from	 the	 parental	 vessels,	 invade	
through	 matrix,	 proliferate	 and	 form	 capillary	
tubes	 (Folkman,	 2006).	 Anti-angiogenic	 agents	
were	known	to	inhibit	proteases,	suppress	receptor	
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phosphorylation	 or	 disrupt	 endothelia	 tube	
formation	 (Murray,	 2001).	 Ursolic	 acid	 isolated	
from	 Salvia officinalis	 L.,	 significantly	 inhibited	
some	 proteases	 as	 included	 in	 tumor	 invasion	
and	 metastasis	 to	 combat	 with	 the	 pathologies	
including	cancer.	Ursolic	acid	could	be	one	of	the	
potent	candidates	which	affected	endothelial	cell	
migration	 (Jedinak	 et al.,	 2006).	 Anti-angiogenic	










































































Figure 2. Effects of doxorubicin and of the association between doxorubicin and Salvia officinalis L. on ascitic volume 
(ml) (A) and tumor cell concentration (cells x103/ mL) (B). 
(* = p˂0.05; ** = p˂0.01; *** = p˂0.001 as compared to EAC group)
(mean ± SEM) (8 animals/group)
STAN	et al.
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organization,	which	are	known	to	play	important	
roles	 in	 cell	 locomotion	 and	 capillary	 tube	
formation	(Plank	and	Sleeman,	2003).
As	a	conclusion	of	 the	 first	part	of	 the	study,	
the	 association	 between	 doxorubicin	 and	 Salvia 






the	 hematological	 and	 biochemical	 parameters	
were	determined.
The	 development	 of	 EAC	 was	 associated	




of	doxorubicin	and	of	doxorubicin	+ Salvia officinalis 
L.	 it	 seems	 to	maintain	 the	 RBC	 level	 significant	
higher	 than	 those	 found	 in	 EAC	 group.	 The	 RBC	
level	 for	EAC	+	Doxorubicin	+	Salvia officinalis L.	
group	is	superior	to	EAC	+	Doxorubicin	group.	The	
explication	 is	still	unknown,	 the	protective	effect	








also	 increased	 in	 a	 significant	 manner.	 In	 EAC	
inoculated	 groups,	 doxorubicin	 therapy	 lowers	
WBC	count	as	compared	to	untreated	EAC	group,	
but	the	value	remains	much	higher	than	the	control.	





alone.	 All	 leucocyte	 categories	 were	 involved	 in	






tocrit	 (PCT),	 mean	 platelet	 volume	 (MPV)	 and	
distribution	 width	 (PDWs)	 do	 not	 undergo	
significant	statistical	changes	compared	to	control	
and	 EAC	 group	 and	 there	 was	 no	 evidence	 of	
toxicity.	 Neither	 the	 biochemistry	 parameters	
(creatinine,	 urea,	 transaminase)	 do	 not	 show	
significant	statistical	changes	compared	to	control	
and	 to	 EAC	 group,	 during	 the	 two	 weeks	 of	 the	
current	study.
In	 this	 way	we	 demonstrated	 that	 the	 asso-
ciation	 of	 Salvia officinalis	 L.	 to	 Doxorubicin	
provides	 some	 protection	 to	 the	 hematological	
parameters	and	it’s	not	toxic.	
Conclusion
Doxorubicin and Salvia officinalis	L.	combined	
therapy	 seems	 to	 increase	 the	 antiproliferative	
effect	 against	 experimental	 inoculated	 cancer	
cells	(EAC),	without	additional	cytotoxicity.	These	






Group RBC 1012/l HGB g/dl HCT %
Control 8.19±0.40 12.56±1.32 37.21±1.05EAC 6.41±0.37* 10.46±1.05 30.73±1.15*
EAC	+	Doxorubicin 7.13±0.68 10.78±0.80 33.46±2.54
EAC	+	Doxorubicin	+	S. officinalis	L. 7.49±0.50 11.95±0.72 35.81±2.63
Normal	values:	RBC	7-12.5	1012/l	HGB	10.2-18	g/dl	HCT	36-49	%	(Uray,	1992)
			(*=p˂0.05	as	compared	to	control	group)
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in	 adjuvant	 cancer	 therapy.	 To	 this	 end,	 studies	
should	be	continued.
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Group WBC 109/l LYM 109/l MID 109/l GRA 109/l
Control 8.62±1.83 4.29±0.65 0.19±0.07 1.47±0.26EAC 27.22±2.32* 5.17±0.97 0.76±0.15* 15.05±2.79*
EAC	+	Doxorubicin 17.01±2.16a 4.83±0.88 0.37±0.11 7.61±2.20a
EAC	+	Doxorubicin	+
S. officinalis	L.
10.19±1.99a 3.66±0.37a 0.19±0.09a 2.21±0.43a
Normal	values	WBC	6-15	109/l	(Uray,	1992)
			(*=p˂0.05	as	compared	to	control	group;	a=p˂0.05	as	compared	to	EAC	group)
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